Profund Advisors LLC Acquires 9,719 Shares of Moderna, Inc. (NASDAQ:MRNA)

Profund Advisors LLC boosted its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 20.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,218 shares of the company’s stock after acquiring an additional 9,719 shares during the period. Profund Advisors LLC’s holdings in Moderna were worth $6,676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its holdings in Moderna by 15.1% during the 1st quarter. Vanguard Group Inc. now owns 39,036,872 shares of the company’s stock worth $4,159,769,000 after acquiring an additional 5,129,800 shares in the last quarter. Wellington Management Group LLP grew its holdings in Moderna by 28.8% during the 4th quarter. Wellington Management Group LLP now owns 7,225,579 shares of the company’s stock worth $718,584,000 after acquiring an additional 1,614,460 shares in the last quarter. Capital World Investors grew its holdings in Moderna by 0.5% during the 1st quarter. Capital World Investors now owns 3,648,117 shares of the company’s stock worth $388,743,000 after acquiring an additional 18,728 shares in the last quarter. Mawer Investment Management Ltd. boosted its holdings in shares of Moderna by 6.7% in the 1st quarter. Mawer Investment Management Ltd. now owns 1,916,570 shares of the company’s stock valued at $204,230,000 after buying an additional 120,621 shares in the last quarter. Finally, Bellevue Group AG boosted its holdings in shares of Moderna by 27.6% in the 4th quarter. Bellevue Group AG now owns 1,908,420 shares of the company’s stock valued at $189,792,000 after buying an additional 413,095 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on MRNA. Oppenheimer cut shares of Moderna from an “outperform” rating to a “market perform” rating in a report on Friday, September 13th. Piper Sandler lowered their price target on shares of Moderna from $157.00 to $115.00 and set an “overweight” rating on the stock in a report on Friday, September 13th. TD Cowen lowered their price target on shares of Moderna from $70.00 to $60.00 and set a “hold” rating on the stock in a report on Friday, September 13th. HSBC upgraded shares of Moderna from a “reduce” rating to a “hold” rating and set a $82.00 price target on the stock in a report on Wednesday, August 28th. Finally, Leerink Partners lowered their price target on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating on the stock in a report on Tuesday, September 17th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Stock Performance

MRNA opened at $65.69 on Friday. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $170.47. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $25.18 billion, a PE ratio of -4.19 and a beta of 1.68. The firm has a 50 day moving average of $90.07 and a two-hundred day moving average of $110.87.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.47) by $0.14. Moderna had a negative net margin of 116.18% and a negative return on equity of 21.35%. The company had revenue of $241.00 million during the quarter, compared to analyst estimates of $128.41 million. During the same period last year, the firm posted ($3.62) EPS. Moderna’s revenue for the quarter was down 29.9% compared to the same quarter last year. On average, analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current year.

Insiders Place Their Bets

In other Moderna news, CFO James M. Mock sold 1,321 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at approximately $682,754. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $119.96, for a total transaction of $1,799,400.00. Following the completion of the transaction, the director now directly owns 2,224,015 shares of the company’s stock, valued at approximately $266,792,839.40. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The disclosure for this sale can be found here. In the last ninety days, insiders sold 93,158 shares of company stock valued at $11,167,312. 15.70% of the stock is owned by insiders.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.